Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Safety of preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: An interim safety analysis from the phase III PREVENT trial of the AIO/CAOGI/ACO.
Authors
Thorsten Goetze
Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, UCT-University Cancer Center and Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Frankfurt Am Main, Germany
Thorsten Goetze , Pompiliu Piso , Ulli Simone Bankstahl , Claudia Pauligk , Claudia Volk , Fabienne Knapp , Disorn Sookthai , Sylvie Lorenzen , Michael Schenk , Armin Wiegering , Peter Jo , Jens Werner , Jens Peter Hölzen , Daniel E Stange , Alexander Stein , Harald Schmalenberg , Metin Senkal , Salah-Eddin Al-Batran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04447352
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 359)
DOI
10.1200/JCO.2024.42.3_suppl.359
Abstract #
359
Poster Bd #
G20
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: The phase III “PREVENT” trial of the AIO /CAOGI /ACO.
First Author: Thorsten Oliver Goetze
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and short-term efficacy of neoadjuvant FLOT therapy in patients with resectable esophageal squamous cell carcinoma.
First Author: Yuri Yoshinami
Poster
2021 ASCO Annual Meeting
MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer—A randomized, double-blind, placebo-controlled, phase 3 study.
First Author: Yelena Y. Janjigian